# Gabapentin in Patients at Clinical Risk for Psychosis

> **NCT02557945** · PHASE1,PHASE2 · TERMINATED · sponsor: **New York State Psychiatric Institute** · enrollment: 9 (actual)

## Conditions studied

- Clinical High Risk for Psychosis

## Interventions

- **DRUG:** Gabapentin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02557945
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-01
- **Primary completion:** 2016-06-12
- **Final completion:** 2016-06-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Combination of insufficient funding and lack of compelling findings
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02557945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02557945, "Gabapentin in Patients at Clinical Risk for Psychosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02557945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*